In the publication in the European Journal of Cancer, Ellebaek E, et al. emphasized that PD-L1 ≥1% was an independent positive prognostic biomarker for survival in the overall cohort (MSS: HR: 0.66, CI: 0.52, 0.83, p < 0.001), supporting previous exploratory analyses of Checkmate-067, highlighting that improved clinical outcomes with combination therapy are not established in unselected patients with high (≥1%) tumor PD-L1 expression [19]. This evidence concerns the gene CD274 and neoplasm.